Access count of this item: 209

Files in This Item:
File Description SizeFormat 
29_0535.pdf952.69 kBAdobe PDFView/Open
Title: 前立腺肥大症の保存的療法 --オキセンドロンの臨床的検討と尿流量測定・超音波断層法による評価--
Other Titles: CLINICAL STUDIES, UROFLOWMETRIC AND ULTRASONOGRAPHIC EVALUATION OF OXENDOLON ON BENIGN PROSTATIC HYPERTROPHY
Authors: 秋山, 隆弘  KAKEN_name
八竹, 直  KAKEN_name
井口, 正典  KAKEN_name
郡, 健二郎  KAKEN_name
金子, 茂男  KAKEN_name
松浦, 健  KAKEN_name
永井, 信夫  KAKEN_name
栗田, 孝  KAKEN_name
三軒, 久義  KAKEN_name
塩見, 努  KAKEN_name
坂口, 洋  KAKEN_name
藤永, 卓治  KAKEN_name
Author's alias: Akiyama, Takahiro
Yachiku, Sunao
Iguchi, Masanori
Kohri, Kenjiro
Kaneko, Shigeo
Matsuura, Takeshi
Nagai, Nobuo
Kurita, Takashi
Sangen, Hisayoshi
Shiomi, Tsutomu
Sakaguchi, Hiroshi
Fujinaga, Takuji
Issue Date: May-1983
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 29
Issue: 5
Start page: 535
End page: 540
Abstract: 前立腺肥大症65症例でオキセンドロン(Prostetin(R)) 200 mg/週を12回投与した.自覚症状の改善は58.5%にみられ,他覚所見の改善は35.0%にみられた.触診・尿流量測定,経直腸的超音波断層法による検討を含め自・他覚所見の推移に相関はみられず,本剤の前立腺腫縮小効果も明確にしえなかった
65 patients with BPH were treated with 200 mg oxendolone (Prostetin®) given intramuscularly at the dose of 200 mg a week for 12 weeks. Subjective symptoms were improved in 58.8 % of these patients. Objective improvement was estimated by rectal palpation, uroflowme try, residual urine volume measurement, urethrocystography, transrectal ultrasonography and endoscopy. Improvement of objective findings were observed to some extent in 35.0% of the patients. But in almost all the patients no evaluable changes were noticed by uroflowmetry or ultrasonography. The changes in the subjective symptoms and objective findings in each case were compared, and a remarkable discrepancy was noticed between the two categories. It is suggested that the subjective improvement in these patients is not based on reduction of prostatic size.
URI: http://hdl.handle.net/2433/120168
Appears in Collections:Vol.29 No.5

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.